Altered Th17/Treg ratio in peripheral blood of systemic lupus erythematosus but not in primary antiphospholipid syndrome by Álvarez Rodríguez, Lorena et al.
ORIGINAL RESEARCH
published: 06 March 2019
doi: 10.3389/fimmu.2019.00391
Frontiers in Immunology | www.frontiersin.org 1 March 2019 | Volume 10 | Article 391
Edited by:
Ricard Cervera,
Hospital Clínic de Barcelona, Spain
Reviewed by:
Manel Juan,
Hospital Clínic de Barcelona, Spain
Pier Luigi Meroni,






This article was submitted to
Autoimmune and Autoinflammatory
Disorders,
a section of the journal
Frontiers in Immunology
Received: 29 October 2018
Accepted: 14 February 2019
Published: 06 March 2019
Citation:
Álvarez-Rodríguez L,
Martínez-Taboada V, Calvo-Alén J,
Beares I, Villa I and López-Hoyos M
(2019) Altered Th17/Treg Ratio in
Peripheral Blood of Systemic Lupus




Altered Th17/Treg Ratio in Peripheral
Blood of Systemic Lupus
Erythematosus but Not Primary
Antiphospholipid Syndrome
Lorena Álvarez-Rodríguez 1, Víctor Martínez-Taboada 2, Jaime Calvo-Alén 3, Iñaki Beares 1,
Ignacio Villa 4 and Marcos López-Hoyos 5*
1 Transplantation and Autoimmunity Laboratory, Rheumatology Department, University Hospital Marqués de
Valdecilla-IDIVAL, Santander, Spain, 2 Faculty of Medicine, Rheumatology Department, University Hospital Marqués de
Valdecilla-IDIVAL, Cantabria University, Santander, Spain, 3 Rheumatology Department, University Hospital Araba,
Vitoria-Gasteiz, Spain, 4 Rheumatology Department, Hospital Sierrallana, Torrelavega, Spain, 5 Immunology Department,
University Hospital Marqués de Valdecilla-IDIVAL, Cantabria University, Santander, Spain
Introduction: The role of the immune response in the pathogenesis of antiphospholipid
syndrome (APS) remains elusive. It is possible that differences in the frequencies of
Th17 cells and/or defects in the immunoregulatory mechanisms are involved in the
pathogenesis of APS. Our aim was to determine the peripheral blood Th cells phenotype
and the circulating cytokine profile in patients with primary APS (pAPS) and compare it
with systemic lupus erythemathosus (SLE) as disease control group.
Methods: The frequencies of circulating regulatory T cells (Tregs) were determined in
PBMCs from 36 patients with pAPS by flow cytometry. As control groups we included
21 age- and gender-matched healthy controls (HC) and 11 patients with SLE. The
suppressive capacity of Tregs was evaluated in vitro by coculture assay. On the other
hand, intracellular cytokine production was assessed in Th1, Th2, and Th17 cells and
circulating IL-6, IL-10, and IL-35 were measured by Cytometric Bead Array and ELISA.
The quantification of Th master gene expression levels was performed by real time
quantitative PCR.
Results: pAPS patients and SLE patients did not show differences in the percentage
or number of Tregs compared to HC. The suppressive capacity of Tregs was also similar
in the three study group. Instead, we found higher FoxP3·mRNA expression levels in
pAPS patients and HC than SLE patients. Regarding the Th17 response, patients with
pAPS and HC showed a significantly lower frequency of circulating Th17 cells than
SLE. However, no differences were observed in the Th1 response between patients and
controls. Thus, increased Th17/Th1 and Th17/Treg ratios were found in SLE patients but
not in pAPS patients. pAPS and SLE patients had higher serum IL-6 levels than HC but
there was not difference between both disease groups. Besides, a significant increase in
the immunosuppressive cytokine levels was observed only in pAPS as compared to HC.
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Conclusions: Our data demonstrate an increased inflammatory profile of peripheral
blood CD4+ T cells from SLE as compared with pAPS mostly due to an increased Th17
response. In conclusion, there seems not to be a direct pathogenic role for Th cells in
pAPS but in SLE.
Keywords: pAPS, SLE, Th1, Th17, Treg, inflammation
INTRODUCTION
The antiphospholipid syndrome (APS) is a systemic autoimmune
inflammatory disease characterized by the presence of serum
antiphospholipid antibodies (aPL) and clinically by vascular
thrombosis and/or obstetric events (1). Several lines of evidence
indicate that aPL contribute to the inflammatory response that
plays an important role in the pathogenesis of APS (2, 3).
Thus, aPL have also emerged as triggers of innate immune
inflammatory pathways in APS, through the activation of toll
like receptors (TLR) (4). Besides, some authors have described
that aPL might induce in vitro Th2 and Th17, but not Th1 or
Treg differentiation (5). Although a clear association between
aPL and clinical manifestations in APS has been established,
the pathogenesis of this syndrome is poorly understood and
it is generally considered multifactorial with an inflammatory
background (6).
On the other hand, the clinical distinction between primary
APS (pAPS) and APS secondary to other autoimmune disorders
is sometimes difficult, especially with APS secondary to systemic
lupus erythematosus (SLE) (7). APS and SLE share some
clinical features, such as multiorgan manifestations, and the
aPL profile and complement activation. At the same time, there
are differences in the serum autoantibodies detected in both
syndromes and we have recently demonstrated that the B cell
phenotype differs between pAPS and SLE (8). From a pathogenic
point of view, both entities are inflammatory disorders in
which the activation of the innate immune response triggers
an exacerbated acquired immune response (9). SLE and pAPS
share an IFN-inducible gene expression signature (10). Besides,
peripheral blood mononuclear B cells from pAPS patients
show an additional monocyte-elicited inflammatory response
demonstrated by increased expression of genes such as TLR8 and
CD14 (11). In any case, both are inflammatory processes that
drive autoantibodies production with some differences, and it
is possible that the different expression of inflammatory genes
may induce different T cells responses (7). However, there are
not studies addressing differences in the circulating numbers or
function of all the main T CD4+ subsets in pAPS, such as Th1,
Th2, Th17, and Tregs, which play important roles in autoimmune
diseases. Differences in the distribution of these cells may favor
the hypotheses for differentiating SLE from pAPS.
Apart from the differences between pAPS and SLE, there
is another important issue regarding the two main clinical
variants of APS: the thrombotic and the obstetric APS (12). The
differentiation between both variants may give and therapeutic
potential. Since, no different autoantibodies have been found
to distinguish vascular and obstetric events, differences in the
circulating T cell phenotype might help. Although there are
scarce works evaluating the peripheral blood T cell phenotype in
pAPS (13, 14), to our knowledge there is no study comparing it
between the vascular and obstetric variants.
In this study, we analyzed in the peripheral blood
compartment the frequencies of Th1, Th2, Th17, and Tregs
in patients with pAPS and compared them with SLE patients
and healthy controls (HC). Besides, we addressed whether there
was any difference for these cells between pAPS with thrombotic
manifestations and obstetric disorders.
MATERIALS AND METHODS
Patients
The present study included 36 patients with pAPS (17 patients
with obstetric complications and 19 patients with thrombotic
phenomena), 11 patients with SLE, and 21 age-matched healthy
controls (HC) without a previous history of infectious, neoplastic
or autoimmune disease. Patients with pAPS were diagnosed
according to the Sydney classification criteria (1). aPL were
considered positive when medium and high titers of serum
aPL were confirmed in two separate determinations at least
12 weeks. The cut off value was set at our laboratory in 20
GPL and MPL for anti-cardiolipin antibodies and 20 U/ml
for anti-β2GPI antibodies (Aeskulab, Wendelsheim, Germany).
pAPS patients were considered as a whole and divided into
vascular and obstetric subtypes. The obstetric complications were
those of classification APS criteria (9 patients had one or more
early pregnancy losses, 12 patients had late pregnancy loss, and
three patients had a live birth with prematurity) and in two
cases non-classification criteria were found (intrauterine growth
restriction). Patients with SLE had to satisfy the ACR 1997
and SLICC 2012 classification criteria (15, 16). All SLE patients
were in remission or presented low disease activity defined by
a score ≤4 in the systemic lupus erythematosus disease activity
index (SLEDAI). The main demographic, clinical, and laboratory
characteristics of the study population are shown in Table 1.
All the patients and controls gave signed informed consent in
accordance with the Declaration of Helsinki, and the study was
approved by the Regional Ethics Committee.
Detection of Intracellular Cytokines in
Circulating Lymphocytes and Monocytes
by Flow Cytometry Analysis
Intracellular cytokine staining is able to detect the production
and accumulation of cytokines in the endoplasmic reticulum
following stimulation. Cells collected in sodium heparin tubes
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TABLE 1 | Demographic and main clinical features of patients with primary antiphospholipid syndrome (pAPS), systemic lupus erythematosus (SLE), and healthy
controls (HC).
HC pAPS Obstetric APS Thrombotic APS SLE
Number of patients, n 21 36 17 19 11
Age, years (mean ± SD) 40.29 ± 11.6 36.36 ± 9.8 34.5 ± 4.2 38.0 ± 12.8 32.8 ± 13.1
Females, n (%) 15 (71.4) 30 (83.3) 17 (100) 13 (68.4) 11 (100)
Follow-up, months (mean ± SD) – – 66.3 ± 22.5 77.7 ± 65.0 121.1 ± 72.5
Clinical manifestations associated with APS, n (%) 0 36 (100) 17 (100) 19 (100) 0
Obstetrical events, n (%) – 17 (47.2) 17 (100) 0 (0) –
Arterial thrombosis, n (%) – 12 (33.3) 0 (0) 12 (63.2) –
Venous thrombosis, n (%) – 7 (19.4) 0 (0) 7 (36.8) –
Positive aPL Serology, n (%) 0 36 (100) 17 (100) 19 (100) 6 (54.5)
Positivity for one Ab, n (%) – 19 (52.8) 11 (64.7) 8 (42.1) 4 (36.3)
Positivity for two Ab, n (%) – 11 (30.5) 5 (29.4) 6 (31.6) 0 (0)
Positivity for three Ab, n (%) – 6 (16.7) 1 (5.9) 5 (26.3) 2 (18.2)
SEROLOGICAL PROFILE
aCL, n(%) – 29 (78.4) 15 (88.2) 14 (73.7) 5 (45.5)
aβGPI, n (%) – 17 (45.9) 7 (41.2) 10 (52.6) 2 (18.2)
Lupus Anticoagulant, n (%) – 15 (40.5) 3 (17.6) 12 (63.2) 3 (27.3)
TREATMENT
Antiaggregant n (%) – 23 (63.9) 16 (94.1) 7 (36.8) 4 (36.4)
Anticoagulant n (%) – 15 (41.7) 0 (0) 15 (78.9) 1 (9.1)
Corticosteroids n (%) – 3 (8.3) 0 (0) 3 (15.8) 3 (27.3)
Antimalarials n (%) – 4 (11.1) 1 (5.9) 3 (15.8) 9 (81.8)
Patients with pAPS were divided into the two groups considered: obstetric and thrombotic.
APS, antiphospholipid syndrome; aPL, antiphospholipid; SLE, Systemic lupus erythematosus; SD, standard deviation; aCL, anticardiolipin; aB2GPI, anti beta 2 glycoprotein; Ab, antibody.
were polyclonally stimulated for 4 h with phorbol 12- myristate
13-acetate (PMA) (Sigma Aldrich, St Louis, Missouri, USA)
and ionomycin (Calbiochem, Gibbstown, New Jersey, USA) in
polystyrene tubes (lymphocytes) in the presence of brefeldin A
(Sigma Aldrich).
After culture, cells were stained with PerCP-conjugated
anti-CD3 (Clone SK7) antibody (BD Biosciences) to identify
T lymphocytes. Thereafter, the red blood cells were lysed with
FACS lysing solution (BD Biosciences), and the mononuclear
cells were permeabilized using FACS Permeabilizing Solution
(BD Biosciences) and intracellularly stained with FITC-
or PE-conjugated cytokine-specific monoclonal antibodies
(BD Biosciences) for IL-2, IFNγ, and IL-4 for lymphocytes
(Clones: IL-2: 5344.11; IFN-γ: 25723.11; IL-4: 3010.211). For
characterization of Th17 cells, cells were stimulated under the
same conditions, followed by surface staining with anti-CD4
APC (clone SK3), anti-CD161 PerCP-Cy 5.5 (clone DX12),
and/or anti-CCR6 PE (clone 11A9) and intracellular staining
with anti-IFNγ-PE (clone 25723.11) and anti-IL-17 FITC (clone
eBio64Dec17). BD Biosciences provided all the antibodies except
Alexa Fluor 488-conjugated anti-IL-17 monoclonal antibody
that was provided by eBiosciences.
The quantification of circulating regulatory T cells (CD4+
CD25hi CD127−/low CD27+ CD62L+ CD45RO+ FoxP3+, and
CD8+CD28−CD27+) was performed by flow cytometry with the
following specific monoclonal antibodies: CD3 (clone SK7), CD4
(SK3), CD8 (SK1), CD25 (clone 2A3), CD27 (clone M-T271),
CD28 (clone, L293), CD45RO (clone UCHL1), CD62L (clone
SK11), CD127 (clone hIL-7R-M21) (BD Biosciences), and FoxP3
(Clone PCH101) (eBiosciences). FoxP3 expression was analyzed
by flow cytometry after intracellular staining using the APC-
anti-human FoxP3 staining set (eBiosciences) and following the
protocol recommended by the manufacturer.
Levels of intracellular cytokine-producing cells together with
surface expression were determined by FACS Canto II Flow
Cytometer (BD Biosciences) and analyzed using FACS Diva
software (BD Biosciences) to quantify the numbers of the
different TCD4+ subsets. Percentages of Th subsets were referred
to the CD4+ T cells.
Detection of Soluble Cytokines in serum
Cytometric Bead Array
The serum was isolated from 4ml of blood obtained in tubes
without additives from each individual and stored at −80◦C
until analysis. The quantitative determination of inflammatory
cytokines in serum was performed using the Cytometric
Bead Array (CBA) Human Th1/Th2/Th17 Cytokine kit (BD
Biosciences; San Diego, California, USA). This kit allows
quantitatively measure interleukin (IL) 2, IL-4, IL-6, IL-10,
Tumor Necrosis Factor (TNF) α, Interferon (IFN) γ, and IL-17A
protein levels in a single sample. The fluorescence produced by
CBA beads was measured on a FACS Canto II Flow Cytometer
(BD Biosciences) and analyzed using FCAP array software (Soft
Flow Inc; New Brighton, MN, USA). Detection limits were 2.6
pg/ml for IL-2, 4.9 pg/ml for IL-4, 2.4 pg/ml for IL-6, 4.5 pg/ml
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for IL-10, 3.8 pg/ml for TNF-α, 3.7 pg/ml for IFN-γ, and 18.9
pg/ml for IL-17A.
ELISA
Serum levels of IL-35 were determined using the commercial
human ELISA kit (USCN Life Science Inc, Wuha, China) in
accordance with the manufacturer’s instructions. The sensitivity
of the ELISA kit for IL-35 was 6.0 pg/ml.
Proliferation Assays
To evaluate the in vitro suppressive capacity of Treg toward
effector T (Teff) cells, FACS-sorted Treg and Teff cells of HC
(n = 9), pAPS (n = 12), and SLE patients (n = 5) were
setup in a coculture assay. PBMCS from sodium-heparinized
peripheral blood were obtained by Ficoll Histopaque 1077 (Sigma
Aldrich) gradient centrifugation. PBMCs were stained with
specific monoclonal antibodies (BD Biosciences): anti-CD25-PE
(Clone 2A3), anti-CD4-PerCP (Clone SK3), and anti-CD127-
Alexa fluor 647 (Clone hIL-7R-M21) for isolation by FACS
sorting of two populations: regulatory T cells and effector T
cells, defined as CD4+ CD25hi CD127−/low and CD4+ CD25−
CD127+, respectively. Purity of FACS-sorted CD4+ CD25hi
CD127−/low T cells was routinely >97%. Following sorting,
effector T cells were labeled with 10µM CFSE (Vybrant CFDA
SE Cell Tracer Kit; Molecular Probes, Eugene, Oregon, USA)
in PBS-1% FBS buffer for 10min at 37◦C. Cells were washed
and resuspended in culture medium at 5 × 105 cells/ml. CFSE-
labeled effector T cells were cultured in vitro (96-well round
bottom plates) alone and cocultured with unlabelled regulatory
T cells (1:1). Cells were either unstimulated or stimulated
with aCD3+aCD28 (Dynabeads human T-activator CD3/CD28
(Invitrogen Dynal, Oslo, Norway) at a bead to-cell ratio 1:1
and incubated at 37◦C and 5% CO2. After 4 days of culture,
cells were harvested, and stained for surface markers and CFSE
signal of gated lymphocytes was analyzed by flow cytometry
using FlowJo Software. Cells were acquired in a FACS Canto II
Flow Cytometer (BD Biosciences). The suppressive capacity of
Tregs toward effector T cells in culture [ratio (1:1)/ Effect] was
expressed as the proliferation index.
Real Time Quantitative PCR
Quantification of T-bet, GATA-3, FoxP3, and RORγ t gene
expression levels in PBMCs from patients and healthy subjects
was performed by real time quantitative PCR. Total RNA
was extracted using Trizol Reagent (Invitrogen, Carlsbad,
CA, USA) and phenol/chloroform extractions method.
The RNA concentration was quantified with a NanoDrop
spectrophotometer (Thermo Scientific, Wilmington, DE, USA)
and RNA integrity was tested by electrophoresis on 1.5% agarose
gel. cDNAs were obtained by retrotranscription using iScript
cDNA synthesis Kit (Bio-Rad Laboratories, CA, USA) according
to the manufacturer’s recommendations in a Master Cycler Pro S
thermal cycler (Eppendorf, Hamburg; Germany).
The primer sequences are the following:
T-bet forward 5′-GATGCGCCAGGAAGTTTCAT-3′,
reverse 5′-GCACAATCATCTGGGTCACATT-3′;





RORγ t forward 5′-CAGTCATGAGAACACAAATTGA
AGTG -3′,
reverse 5′-CAGGTGATAACCCCGTAGTGGAT -3.




Real-time quantitative PCR was carried out using the Sso Fast
Evagreen Supermix (Bio-Rad) according to the manufacturer’s
recommendations. PCR reactions were conducted in duplicate
in a CFX96 detection system (Bio-Rad) and raw data were
converted into the threshold cycle (Ct) values for each sample.
Relative quantification was analyzed by the comparative Ct
method, also referred to as 2−11Ct method, described by
Schmittgen and Livak (17). The p- values were calculated based
on a Student’s t-test for each gene in patients and healthy subjects.
Statistical Analysis
The normality was assessed using the Shapiro Wilk test.
The data from the healthy controls and patient groups
were first analyzed by Kruskall-Wallis test. The statistical
comparisons of data between different pathologies and healthy
controls were performed using the Mann-Whitney U-test.
Correlations were assessed using Spearman’s rank correlation
coefficient. Differences were considered significant when p values
were < 0.05. All the statistical analysis of data was carried out
with the SPSS 15.0 software (Chicago, Illinois, USA).
RESULTS
Circulating T Cells With Regulatory
Phenotype in Patients With pAPS and SLE
We first looked at the main circulating regulatory T cells subtype
(Tregs), identified as CD4+CD25hiCD127lowFoxP3+ in fresh
peripheral blood samples by flow cytometry and compared pAPS
and SLE patients. No differences neither in the percentages or
numbers of these circulating Tregs were found between the
pAPS patients and SLE patients and neither between both disease
groups and HC (Figure 1A). However, we found peripheral
blood frequencies of other regulatory T cell subset, defined as
CD8+CD28−CD27+, significantly decreased in pAPS compared
to SLE patients (p = 0.019) but not to HC (Figure 1B). SLE
patients showed no differences in the CD8+CD28−CD27+
compared to HC.
We subdivided pAPS patients in two groups according to their
main clinical features, thrombotic or pregnancy complications.
Thus, those patients with thrombotic APS had a significant
decreased frequency of CD8+CD28−CD27+cells as compared to
SLE patients (p = 0.026). In the case of patients with obstetric
pAPS, differences did not reach statistical significance (p= 0.055)
(Figure 1B). Frequencies and absolute numbers of peripheral
blood FoxP3+ Tregs did not differ between the two subgroups
of pAPS (Figure 1A).
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FIGURE 1 | Frequencies and numbers of peripheral blood regulatory T cells: CD4+ CD25hi CD127−/low CD27+ CD62L+ CD45RO+ FoxP3+ (A) and
CD8+CD28−CD27+ (B) cells in patients with primary antiphospholipid syndrome (pAPS, n = 36) and systemic lupus erythematosus (SLE, n = 11) and healthy
controls (HC, n = 21). Data of pAPS patients were also analyzed according to the two pAPS variants (lower panel of figures): obstetric (n = 17) and thrombotic (n =
19) variants. Frequencies of CD8+CD28−CD27+ cells in pAPS patients were significantly lower than in SLE patients and mainly due to the thrombotic patients (B),
calculated by Mann-Whitney U test. There was no significant difference for CD4+ Tregs (A). Data are expressed as the median and interquartile range. HC, healthy
controls; pAPS, primary antiphospholipid syndrome; SLE, systemic lupus erythematosus.
Patients With pAPS Display Decreased
Frequencies of Peripheral Blood Th17 Cells
Than Patients With SLE
Th17 and Th1 cell responses in peripheral blood from patients
and healthy subjects were analyzed by measuring intracellular
cytokine production by CD4+ T cells. The frequencies of
Th17 cells, defined as CD4+CD161+CCR6+ IL17+IFN-γ−,
were significantly decreased in pAPS patients, and also in
HC, compared to SLE patients (p = 0.001 and p = 0.005,
respectively), although no differences were found between
APS vs. HC (Figure 2A). Interestingly, both patients with
obstetric and thrombotic pAPS showed a lower frequency
of Th17 cells compared to SLE (p = 0.002 and p =
0.005, respectively) (Figure 2B). In addition, as shown in
Figure 2C, patients with pAPS had a lower frequency of
CD4+IL-17+ IFN+ cells than SLE patients (p = 0.021). More
specifically, those cells were also significantly decreased in
patients with obstetric pAPS compared to HC, thrombotic
pAPS and SLE (p = 0.015, p = 0.032, and p = 0.006,
respectively) (Figure 2D).
Regarding Th1 response, there was a similar proportion of
CD4+IL17−IFN-γ+ T cells in both patient groups and HC
(Figure 2C). No difference was found for Th2 cells, quantified as
producers of IL-4 (Figure 2D). Additionally, we also measured
intracellular cytokine-producing monocytes in peripheral blood
and did not observe differences in the percentages between
patients and controls (Supplementary Figure 1).
Altered Th17/Th1 and Th17/Treg Balance in
SLE Patients but Not in pAPS Patients
The relation between Th17 cells to Th1 or regulatory T cells was
determined in patients and controls by calculating the Th17/Th1
and Th17/Treg ratios. Th17/Th1 cell ratio was significantly
lower in pAPS than in SLE patients (p = 0.015), although
similar compared to HC (Figure 3A). We also noticed significant
differences in the Th17/Th1 cells ratio in patients with obstetric
and thrombotic pAPS compared to SLE (p= 0.021 and p= 0.046,
respectively). In addition, HC had a lower Th17/Th1 cell ratio
than SLE patients (p= 0.033) (Figure 3A).
Frontiers in Immunology | www.frontiersin.org 5 March 2019 | Volume 10 | Article 391
Álvarez-Rodríguez et al. Th Cells in pAPS/SLE
FIGURE 2 | Frequencies of Th17 cells (A,B), Th1 (C), and Th2 (D) cells in patients with primary antiphospholipid syndrome (pAPS, n = 37) and systemic lupus
erythematosus (SLE, n = 11) and healthy controls (HC, n = 21). Th17 cells were divided in two subtypes: conventional Th17 (IL-17+ IFN-γ−) and Th17Th1 (IL-17+
IFN-γ+). Data from pAPS patients were analyzed globally or separately by obstetric (n = 17) or thrombotic (n = 19) pAPS were analyzed. Only significant differences
are displayed when p value was < 0.05 by Mann-Whitney U-test. Data are expressed as the median and interquartilic range and referred to the gate of CD4+ T cells.
HC, healthy controls; pAPS, primary antiphospholipid syndrome; SLE, systemic lupus erythematosus.
FIGURE 3 | Ratios of circulating Th17/Th1 (A) and Th17/Treg (B) cells in patients with primary antiphospholipid syndrome (pAPS, n = 36) and systemic lupus
erythematosus (SLE, n = 11) and healthy controls (HC, n = 21). Th17 were considered as T CD4+ cells IL-17+ IFN-γ−) whereas the Th1 cells were IL-17− IFN-γ+).
Treg cells were defined as CD4+ CD25hi CD127−/low CD27+ CD62L+ CD45RO+ FoxP3+. Data of pAPS patients were also analyzed according to the two pAPS
variants: obstetric (n = 17) and thrombotic (n = 19) variants. The level of significant differences between groups are indicated only when p value was < 0.05 by
Mann-Whitney U-test. Data are expressed as the median and interquartilic range. HC, healthy controls; pAPS, primary antiphospholipid syndrome; SLE, systemic
lupus erythematosus.
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Similarly, Th17/Treg cell ratio was significantly increased in
SLE patients compared to HC and pAPS patients (p = 0.005 and
p = 0.002, respectively) (Figure 3B), particularly with obstetric
pAPS patients (p = 0.004) (Figure 3B). Again, these differences
were not found in the pAPS patients compared to HC.
We also measured the expression of specific Th transcription
factors (Figure 4). SLE patients had lower FoxP3 mRNA
expression levels compared to HC and pAPS (p = 0.007 and p
= 0.008, respectively). In agreement with cell ratios described
above, those patients with obstetric pAPS had higher FoxP3
mRNA expression levels than SLE patients (p= 0.004) (Figure 4).
On the other hand, RORγt mRNA levels were significant reduced
in SLE patients compared to HC (p = 0.018) but not with pAPS.
Besides, pAPS patients, especially obstetric patients, had also
significant reduced RORγt mRNA expression levels compared to
HC (p= 0.006).
Patients With APS Have Higher Serum
Concentration of Immunosuppresive
Molecules Than Healthy Controls
IL-6 plays a major role in the differentiation to Th17 cells.
Possibly, an excess of IL-6 could tip the balance toward the
induction of Th17 cells. As shown in Figure 5, pAPS and SLE
patients had higher IL-6 levels than HC (p = 0.048 and p =
0.036, respectively) but no differences were found between APS
and SLE. Besides, both obstetric and thrombotic APS displayed
similar IL-6 levels and not different from SLE (Figure 5). No
differences in other soluble inflammatory cytokine levels such as
IL-2, IL-4, TNF-α, INF-γ, and IL-17 were observed among three
groups (Supplementary Figure 2).
One of the Treg-mediated suppression mechanisms is the
production of immunosuppressive cytokines, such as IL-10 and
IL-35. Circulating serum levels of IL10 were significantly higher
in patients with pAPS than HC (p = 0.002). These differences
were markedly increased in those patients with thrombosis (p
= 0.001) (Figure 5). Likewise, IL-35 serum levels were also
significantly increased in pAPS compared HC (p = 0.045)
(Figure 5). Importantly, patients with SLE did not show any
significant difference in these immunosuppressive molecules,
although showed a trend to have lower serum levels (Figure 5).
Normal Suppressive Capacity of Tregs in
Patients With pAPS and SLE
According to ours results, we investigated the in vitro suppressive
capacity of Tregs toward effector T cells, by co-culture assay, and
the cytokine producing into culture supernatants (Figure 6).
The suppressive capacity of Tregs was similar in three study
groups (Figure 6). In addition, patients with pAPS or SLE did
not show differences in the concentration of suppressive IL-10
nor IL-35 (Figure 5).
DISCUSSION
The hypothesis of the present work is that pAPS and SLE
pathogenesis may be differentiated by a distinct balance between
Th17 and Tregs in peripheral blood that could result in
an increased inflammatory response in SLE as compared to
pAPS. There are a number of studies showing an increased
inflammatory effector CD4+ T cells response in SLE (18–23).
Treg cells have been extensively studied in peripheral blood
of SLE patients, although with contradictory results (24–27).
However, data of different Th subsets in pAPS are very scarce
and with limited methodological approach (13, 14). Simonin et
al. (28) studied the peripheral naïve, memory and effector B
and T cell compartments but not Th subsets in 22 patients with
pAPS and 49 controls. They found disturbances in the B cell
compartment but not in T cells, which only showed a general
reduction in comparison to controls. In the present work, we
investigated the balance between immunoregulatory and effector
immune response by measuring the number of circulating Th1,
Th17, and Tregs cells as well as serum levels of cytokines in pAPS
and compared them with SLE. As a limitation, the SLE patient
number was low as compared with pAPS (11 vs. 37) and all of
them were female what can add a bias to the analysis but it was
not possible to recruit SLE male patients for the study. More
importantly, we selected two well-established groups of pAPS
and SLE because they had a long-term follow-up to exclude a
possible progression to secondary APS from SLE, although we
are aware that some authors consider pAPS and SLE as one
single disease (29). Furthermore, numbers of pAPS patients were
balanced between obstetric and thrombotic manifestations in the
present work, in contraposition to previous studies that even
do not differentiate them. Although it is possible that obstetric
patients could develop thrombotic events, the time of follow-up
is long-enough to differentiate both subtypes in the present work.
In our experience, patients with obstetric pAPS rarely develop
thrombotic pAPS (30).
Our results showed an equivalent Th17 response in pAPS to
HC but decreased as compared to SLE patients. These data differ
from those found by Jakiela et al. (14) that found an increased
frequency of effector T CD4+ cells including Th17 in pAPS as
compared to HC. This increase was even more evident in those
pAPS patients with high titers of aPL IgG antibodies. We did
not observe such an association between aPL titers and Th17
cells in peripheral blood. One possible explanation may have to
be with the low serum aPL titers in our long-term patients in
whom they can decrease. However, the strength of the present
work is the comparison we made between pAPS and SLE patients
since the latter were with low disease activity (SLEDAI ≤4) in
order to exclude any influence of the systemic inflammatory
response in the immunoregulatory phenotype. We also looked
at the percentages of circulating IFN-γ producing Th1 cells but
there was no change between both disease groups and between
any disease group and HC. For intracellular cytokine-producing
CD4+ T cells we used the percentages of cells referred to CD4+ T
cells instead of absolute numbers, since the data were obtained
after in vitro stimulation. Besides, there was no significant
difference for absolute numbers of any lymphoid cell (CD3+,
CD4+, CD8+, CD19+, and CD16+CD56+) in peripheral blood
(Supplementary Figure 3) and, consequently, we considered
that frequencies and absolute numbers were equivalent.
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FIGURE 4 | mRNA expression of transcription factors for Th differentiation. Relative fold change expression of mRNA quantified by real time quantitative PCR of T-bet,
GATA-3, FoxP3, and RORγt in patients (15 pAPS patients: 8 obstetric and 7 arterial thrombosis; 10 SLE patients) and healthy controls (n: 10) is displayed. pAPS were
subdivided into the main two variants: obstetric and thrombotic. Level of significance is only shown when p value was < 0.05 by Student-t test between groups for
each gene. Data are expressed as the mean value. HC, healthy controls; pAPS, primary antiphospholipid syndrome; SLE, systemic lupus erythematosus.
FIGURE 5 | Serum cytokines levels in patients with primary antiphospholipid syndrome (pAPS, n = 37) and systemic lupus erythematosus (SLE, n = 11) and healthy
controls (HC, n = 21). Serum IL-6 and IL-10 levels were assessed by CBA whereas serum levels of IL-35 were measured by ELISA. The level of significant differences
between groups are indicated only when p value was < 0.05 by Mann-Whitney U-test. Data are expressed as the median and interquartile range. HC, healthy
controls; pAPS, primary antiphospholipid syndrome; SLE, systemic lupus erythematosus.
Isolated analysis of Th17 cells does not give enough
information about the effector immune response since regulatory
T cells may balance it (31). In this regard, peripheral blood Tregs
did not differ between both disease groups and HC. This is in
disagreement with other authors, that found lower frequencies
of Tregs in 20 pAPS patients than in HC, although the panel of
antibodies to define Tregs was shorter than the one employed in
our study (32). We did not find an increase in Tregs as described
by other authors in SLE (25, 26), but it could be attributed to
the low disease activity of our SLE cohort. Neither, there was any
significant difference in the frequency of circulating Th2 cells. As
a consequence, we only observed significantly higher Th17/Tregs
ratios in SLE patients than in pAPS patients and HC. Again,
Th17/Tregs ratios did not differ between pAPS patients and HC.
Likewise, there was a similar increased Th17/Th1 ratio in SLE.
These data indicate that SLE, despite our cohort was not clinically
active, showed an unbalanced inflammatory state mainly due to
a higher Th17 response, with no important changes in Th1 or
regulatory T cell responses. This finding was relevant since our
SLE patients were mostly on antimalarial treatment, which have
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FIGURE 6 | Suppression function of CD4+ Treg cells in in vitro culture with polyclonally stimulated CD4+ effector T cells. FACS-sorted Treg (CD4+ CD25hi
CD127−/low) and effector (Teff, CD4+CD25−CD127+) T cells of HC (n = 9), pAPS (n = 12), and SLE patients (n = 5) were setup in a coculture assay. Following
sorting, effector T cells were labeled with 10µM CFSE. CFSE-labeled Teff cells were cultured in vitro alone and cocultured with unlabeled Treg cells (1:1). Cells were
either unstimulated or stimulated with anti-CD3+anti-CD28 antibodies at a bead to cell ratio 1:1 and incubated for 4 days. Then, cells were harvested and analyzed by
flow cytometry. (A) Shows a representative experiment with only Teff cells stimulated (left) or with the addition of Treg cells to stimulated Teff cells (right). The
suppressive capacity of Treg toward effector T cells in culture [ratio (1:1)/ Effect] was expressed as the proliferation index with respect to the proliferation of Teff cells
stimulated without Treg cells. (B) Represents the median proliferation index in each group and interquartilic range.
been described to decrease Th17-related cytokines in SLE (33).
Our cellular findings were also observed for mRNA expression
in PBMC. Thus, FoxP3 mRNA expression was significantly
decreased in SLE as compared with HC and pAPS, as previously
described (34). Such a decrease is even more significant since
more SLE than pAPS patients were receiving corticosteroids what
have been described as inducing factor of FOXP3 expression (34).
On the other hand, ROR-gamma T expression was lower in SLE
patients than in HC but not in pAPS. No important changes were
detected for the other two Th master genes expression, T-bet or
Gata-3. Regarding regulatory mechanisms, we did find decreased
numbers of CD8+CD28−CD27+ cells in pAPS patients, another
type of regulatory T cells different from the most studied Tregs
CD4+ cells, and that has been described in mouse models
and human liver transplantation (35), as well as in organ-
specific autoimmune diseases (36). These cells might be induced
by peripheral mechanisms and secreted suppressive cytokines,
such as IL-10 or TGF-β (37). Importantly enough, there was
a significant increase of the immunoregulatory IL-10 in serum
from pAPS patients as compared with HC. Such a difference was
not observed for SLE. To the best of our knowledge there are
not report showing such a finding. The only related finding has
to be not with an increase but a decrease of another regulatory
cytokine, TGF-beta (14). The increase we found in serum IL-10
might support our theory of a higher immune regulation in pAPS
than in SLE.
All our data together might suggest that the adaptative
immune response is not significantly altered in pAPS as
compared to the hallmark systemic autoimmune disease,
SLE, despite pAPS is also an autoimmune response with
autoantibodies production. These data differ from Xiao et al.
(5) that found a diminished Th1/Th2 ratio and increased Th17
and decreased Tregs in culture of PBMC from HC with different
concentrations of aPL. However, the experimental approach was
different from ours since they focused on the in vitro effect of
aPL on Th differentiation. In opposition to our findings, other
authors described that β2GPI- reactive T cells might provide T
cell help to B cells to induce the production of class-switched
aPL in APS which was also associated with certain HLA class
II genes (38). However, such a Th cell response is not specific
of APS since it has been described in APS but also in SLE and
in APS-negative subjects (39, 40). The specificity seems to be
specific of the β2GPI epitope used to stimulate the Th cells (38).
Besides, these β2GPI- reactive T cells have been found increased
in APS subjects with subclinical (41) and clinical atherosclerosis
(42). Interestingly, Benagiano et al. (42) evidenced domain I
β2GPI- specific Th1 infiltrates in atherosclerotic plaques of pAPS
patients what supported the role of the adaptative response in the
induction of aPL and the plaque formation in pAPS. However,
they did not studied the possible role of T follicular helper cells
that provides the signal to B cells in the follicle to generate switch
class and affinity maturated autoantibodies (43). In the present
study, we neither focused in T follicular helper cells. Evidences
suggest a higher involvement of innate response, as demonstrated
by increased gene transcription of TLR8 in pAPS (11) or
β2GPI-anti-β2GPI immunocomplex stimulation of monocytes
through TLR4 (44). Furthermore, APS patients demonstrated
increased expression of adhesion molecules in endothelium
(45). On the other hand, neutrophils of pAPS patients
display a pro-inflammatory gene signature (46). All the data
together establish pAPS as an inflammatory autoimmune disease,
although it does not induce a pro-inflammatory Th17 response
as inflammation in SLE does in the present work and previous
reports (18–23).
There exists a clear debate about the inflammation associated
with vascular pAPS and obstetric pAPS (12). Antiphospholipid
syndrome has two clinical subtypes according to obstetric or
thrombotic events. From the laboratory diagnostic criteria, they
do not differ and have the same aPL profile although recent
evidences show also differences. In some cases, vascular and
obstetric manifestations occur in the same patient, although
pAPS is a stable disease in which the patient that presents
with obstetric pAPS does not develop thrombosis and vice
versa. This suggests that obstetric and vascular pAPS could
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be different diseases. Apart from clinic-epidemiological data,
the study of immune-mediated mechanisms involved in both
clinical variants may help to determine whether they are the
same or different disease with therapeutic implication. Evidences
suggest that vascular pAPS courses with complement activation
that subsequently would induce thrombi, but with very low
inflammation (12). On the contrary, obstetric pAPS would be
induced by inflammatory mechanisms, although the presence of
inflammatory cells in placenta of pAPS is very uncommon (47).
Our data, although obtained from peripheral blood lymphocytes,
point to a more inflammatory profile in thrombotic than in
obstetric pAPS. Indeed, patients with thrombotic pAPS had a
higher load of aPL than obstetric one (Table 1) and it could
explain some of the differences found in Th cells between
both pAPS subtypes. Furthermore, the decreased percentages
of Th17Th1 cells (also considered as the subtype Th17.1)
could explain the lower expression of ROR-γt, which is usually
expressed in Th17Th1 cells together with T-bet (48). In any
case, the number of circulating proinflammatory Th17 cells
was always lower in any subtype of pAPS than in SLE. It
is possible that the CD4+T cells phenotype in peripheral
blood is not enough to show important differences between
vascular and obstetric pAPS or, at least, does not correlate
with previously described tissue cellular infiltrates in both
pAPS variants.
Finally, we are aware of the limitation of our study regarding
the possible effect of the different treatments in SLE and
pAPS that were not considered as confounding factors. Patients
with pAPS were treated with antiplatelet and/or anticoagulant
therapies, whereas SLE patients were treated with antimalarials
and steroids. To the best of our knowledge, we have not found
any influence of treatments in pAPS on Th differentiation in
the literature, although there is one study showing in vitro
the inhibitory effect of prasugrel on effector Th cells that were
induced to an inflammatory phenotype by addition of plateles
(49). Patients with pAPS included in the present study did not
receive prasugrel. However, the effect of antimalarials to inhibit
Th17-mediated immunity is well-known (33, 50). The effect of
corticosteroids in Th1 and Th17 cells has been already studied
and demonstrated (51, 52). This reinforces our findings showing
a stronger Th17 response in SLE than in pAPS, despite the
suppressive effect of treatment.
In conclusion, our data demonstrated an increased
inflammatory Th17 phenotype in patients with SLE that
was not observed in pAPS patients who showed a similar
phenotype to HC. In addition, thrombotic pAPS showed higher
levels of peripheral blood Th17 than obstetric pAPS. Altogether,
these data bring important information about the therapeutic
possibilities in pAPS.
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Supplementary Figure 1 | Frequencies of peripheral blood monocytes secreting
inflammatory cytokines in patients with primary antiphospholipid syndrome (pAPS,
n = 37) and systemic lupus erythematosus (SLE, n = 11), and healthy controls
(HC, n = 21). Data from pAPS patients were analyzed globally or separately by
obstetric (n = 17) or thrombotic (n = 19) pAPS were analyzed. Monocytes from
peripheral blood were intracellular stained with monoclonal antibodies specific for
IL-1β, TNF-α, and IL-6, after in vitro stimulation with LPS for 4 hours. No
significant differences were found among groups by Mann-Whitney U-test. Data
are expressed as the median and interquartile range and referred to the gate of
CD4+ T cells. HC, healthy controls; pAPS, primary antiphospholipid syndrome;
SLE, systemic lupus erythematosus.
Supplementary Figure 2 | Serum cytokines levels in patients with primary
antiphospholipid syndrome (pAPS, n = 37) and systemic lupus erythematosus
(SLE, n = 11), and healthy controls (HC, n = 21). Data of pAPS patients were also
analyzed according to the two pAPS variants (lower panel of figures): obstetric
(n = 17) and thrombotic (n = 19) variants. Serum cytokine levels (IL-2, TNF-α,
IFN-γ, IL-4, IL-17) were assessed by CBA. No significant differences were found
among groups. Data are expressed as the median and interquartile range. HC,
healthy controls; pAPS, primary antiphospholipid syndrome; SLE, systemic lupus
erythematosus.
Supplementary Figure 3 | Absolute numbers of peripheral blood total
lymphocytes (A) and lymphocyte subsets (absolute numbers in (B) and
frequencies in (C): CD3+, CD4+, CD8+, CD19+, and CD16+/CD56+) in patients
with primary antiphospholipid syndrome (pAPS, n = 37) and systemic lupus
erythematosus (SLE, n = 11) and healthy controls (HC, n = 21). Data of pAPS
patients were also analyzed according to the two pAPS variants (lower panel of
figures): obstetric (n = 17) and thrombotic (n = 19) variants. No significant
differences were found among groups. Data are expressed as the median and
interquartile range. HC, healthy controls; pAPS, primary antiphospholipid
syndrome; SLE, systemic lupus erythematosus.
REFERENCES
1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al.
International consensus statement on an update of the classification criteria
for definite antiphospholipid syndrome (APS). J Thromb Haemost. (2006)
4:295–306. doi: 10.1111/j.1538-7836.2006.01753.x
2. Manzi S, Ahearn JM, Salmon J. New insights into complement: a mediator of
injury and marker of disease activity in systemic lupus erythematosus. Lupus.
(2004) 13:298–303. doi: 10.1191/0961203303lu1016oa
3. Groot PG De, Urbanus RT. Antiphospholipid syndrome – not a
non inflammatory disease. Sem Thromb Hemost. (2015) 41:607–14.
doi: 10.1055/s-0035-1556725
Frontiers in Immunology | www.frontiersin.org 10 March 2019 | Volume 10 | Article 391
Álvarez-Rodríguez et al. Th Cells in pAPS/SLE
4. Abrahams VM, Chamley LW, Salmon JE. Emerging treatment models
in rheumatology: antiphospholipid syndrome and pregnancy: pathogenesis
to translation. Arthritis Rheumatol. (2017) 69:1710–21. doi: 10.1002/
art.40136
5. Xiao J, Zhu F, Liu X, Xiong J. Th1/Th2/Th17/Treg expression in cultured
PBMCs with antiphospholipid antibodies. Mol Med Rep. (2012) 6:1035–9.
doi: 10.3892/mmr.2012.1055
6. Arachchillage DRJ, Laffan M. Pathogenesis and management of
antiphospholipid syndrome. Br J Haematol. (2017) 178:181–95. doi: 10.1111/
bjh.14632
7. Belizna C, Stojanovich L, Cohen-Tervaert JW, Fassot C, Henrion D, Loufrani
L, et al. Primary antiphospholipid syndrome and antiphospholipid syndrome
associated to systemic lupus: are they different entities? Autoimmun Rev.
(2018) 17:739–45. doi: 10.1016/j.autrev.2018.01.027
8. Álvarez-Rodríguez L, Riancho-Zarrabeitia L, Calvo-Alén J, López-
Hoyos M, Martínez-Taboada V. Peripheral B-cell subset distribution
in primary antiphospholipid syndrome. Int J Mol Sci. (2018) 19:E589.
doi: 10.3390/ijms19020589
9. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid
syndrome — NEJM. N Engl J Med. (2013) 368:1033–44.
doi: 10.1056/NEJMra1112830
10. Perez-Sanchez C, Barbarroja N, Messineo S, Ruiz-Limon P, Rodriguez-Ariza
A, Jimenez-Gomez Y, et al. Gene profiling reveals specific molecular
pathways in the pathogenesis of atherosclerosis and cardiovascular
disease in antiphospholipid syndrome, systemic lupus erythematosus and
antiphospholipid syndrome with lupus. Ann Rheum Dis. (2015) 74:1441–9.
doi: 10.1136/annrheumdis-2013-204600
11. Bernales I, Fullaondo A, Marín-Vidalled MJ, Ucar E, Martínez-Taboada V,
López-Hoyos M, et al. Innate immune response gene expression profiles
characterize primary antiphospholipid syndrome.Genes Immun. (2008) 9:38–
46. doi: 10.1038/sj.gene.6364443
12. Meroni PL, Borghi MO, Grossi C, Chighizola CB, Durigutto P,
Tedesco F. Obstetric and vascular antiphospholipid syndrome: same
antibodies but different diseases? Nat Rev Rheumatol. (2018) 14:433–40
doi: 10.1038/s41584-018-0032-6
13. Popovic-Kuzmanovic D, Novakovic I, Stojanovich L, Aksentijevich I, Zogovic
N, Tovilovic G, et al. Increased activity of interleukin-23/interleukin-17
cytokine axis in primary antiphospholipid syndrome. Immunobiology. (2013)
218:186–91. doi: 10.1016/j.imbio.2012.03.002
14. Jakiela B, Iwaniec T, Plutecka H, Dziedzina S, Musial J. Signs of
impaired immunoregulation and enhanced effector T-cell responses
in the primary antiphospholipid syndrome. Lupus. (2015)1–10.
doi: 10.1177/0961203315618267
15. Hochberg MC. Updating the American College of Rheumatology revised
criteria for the classification of systemic lupus erythematosus. Arthritis
Rheum. (1997) 40:1725. doi: 10.1002/1529-0131(199709)40:9<1725::AID-
ART29>3.0.CO;2-Y
16. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al.
Derivation and validation of the systemic lupus international collaborating
clinics classification criteria for systemic lupus erythematosus. Arthritis
Rheum. (2012) 64:2677–86. doi: 10.1002/art.34473
17. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative
CTmethod. Nat Protoc. (2008) 3:1101–8. doi: 10.1038/nprot.2008.73
18. Rother N, Van der Vlag J. Disturbed T cell signaling and altered Th17 and
regulatory T cell subsets in the pathogenesis of systemic lupus erythematosus.
Front Immunol. (2015) 6:10. doi: 10.3389/fimmu.2015.00610
19. Kubo S, Nakayamada S, Yoshikawa M, Miyazaki Y, Sakata K, Nakano K,
et al. Peripheral immunophenotyping identifies three subgroups based on T
cell heterogeneity in lupus patients. Arthritis Rheumatol. (2017) 69:2029–37.
doi: 10.1002/art.40180
20. Oke V, Brauner S, Larsson A, Gustafsson J, Zickert A, Gunnarsson I, et
al. IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets
in systemic lupus erythematosus (SLE). Arthritis Res Ther. (2017) 19:139.
doi: 10.1186/s13075-017-1344-7
21. Chen M, Chen X, Wan Q. Altered frequency of Th17 and Treg cells in
new-onset systemic lupus erythematosus patients. Eur J Clin Invest. (2018)
48:e13012. doi: 10.1111/eci.13012
22. Tsanaktsi A, Solomou EE, Liossis SNC. Th1/17 cells, a subset of Th17 cells, are
expanded in patients with active systemic lupus erythematosus.Clin Immunol.
(2018) 195:101–6. doi: 10.1016/j.clim.2018.08.005
23. Zhong W, Jiang Z, Wu J, Jiang Y, Zhao L. CCR6 + Th cell distribution
differentiates systemic lupus erythematosus patients based on anti-dsDNA
antibody status. Peer J. (2018) 6:e4294. doi: 10.7717/peerj.4294
24. Miyara M, Gorochov G, Ehrenstein M, Musset L, Sakaguchi S, Amoura
Z. Human FoxP3 + regulatory T cells in systemic autoimmune
diseases. Autoimmun Rev. (2011) 10:744–55. doi: 10.1016/j.autrev.2
011.05.004
25. Alexander T, Sattler A, Templin L, Kohler S, Groß C, Meisel A,
et al. Foxp3+ Helios+ regulatory T cells are expanded in active
systemic lupus erythematosus. Ann Rheum Dis. (2013) 72:1549–58.
doi: 10.1136/annrheumdis-2012-202216
26. Ohl K, Tenbrock K. Regulatory T cells in systemic lupus erythematosus. Eur J
Immunol. (2015) 45:344–55. doi: 10.1002/eji.201344280
27. Costa N, Marques O, Godinho SI, Carvalho C, Leal B, Figueiredo AM, et al.
Two separate effects contribute to regulatory T cell defect in systemic lupus
erythematosus patients and their unaffected relatives. Clin Exp Immunol.
(2017) 189:318–30. doi: 10.1111/cei.12991
28. Simonin L, Pasquier E, Leroyer C, Cornec D, Lemerle J, Bendaoud B,
et al. Lymphocyte disturbances in primary antiphospholipid syndrome
and application to venous thromboembolism follow-up. Clin Rev Allergy
Immunol. (2016) 3878:1–14. doi: 10.1007/s12016-016-8568-1
29. Shoenfeld Y, Meroni PL, Toubi E. Antiphospholipid syndrome and
systemic lupus erythematosus: are they separate entities or just clinical
presentations on the same scale? Curr Opin Rheumatol. (2009) 21:495–500.
doi: 10.1097/BOR.0b013e32832effdd
30. Riancho-Zarrabeitia L, Daroca G, Muñoz P, López-Hoyos M, Haya A,
Martínez-Taboada VM. Serological evolution in women with positive
antiphospholipid antibodies. Sem Arthritis Rheuma. (2017) 47:397–402.
doi: 10.1016/j.semarthrit.2017.05.001
31. San Segundo D, López-Hoyos M, Fernández-Fresnedo G, Benito MJ,
Ruiz JC, Benito A, et al. TH17 versus treg cells in renal transplant
candidates: effect of a previous transplant. Transplant Proc. (2008) 40:2885–8.
doi: 10.1016/j.transproceed.2008.09.043
32. Dal Ben ERR, Do Prado CH, Baptista TSA, Bauer ME, Staub HL. Decreased
levels of circulating CD4+CD25+Foxp3+ regulatory T cells in patients
with primary antiphospholipid syndrome. J Clin Immunol. (2013) 33:876–9.
doi: 10.1007/s10875-012-9857-y
33. da Silva JC, Mariz HA, da Rocha LF Jr, de Oliveira PSS, Dantas AT,
Duarte ALBP, et al. Hydroxychloroquine decreases Th17-related cytokines
in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics.
(2013) 68:766–71. doi: 10.6061/clinics/2013(06)07
34. Prado C, Gómez J, López P, de Paz B, Gutiérrez C, Suárez A. Dexamethasone
upregulates FOXP3 expression without increasing regulatory activity.
Immunobiology. (2011) 216:386–92. doi: 10.1016/j.imbio.2010.06.013
35. Suzuki M, Konya C, Goronzy JJ, Weyand CM. Inhibitory CD8+T
cells in autoimmune disease. Hum Immunol. (2008) 69:781–9.
doi: 10.1016/j.humimm.2008.08.283
36. Mikulkova Z, Praksova P, Stourac P, Bednarik J, Strajtova L, Pacasova R, et
al. Numerical defects in CD8+CD28- T-suppressor lymphocyte population in
patients with type 1 diabetes mellitus and multiple sclerosis. Cell Immunol.
(2010) 262:75–9. doi: 10.1016/j.cellimm.2010.02.002
37. Vuddamalay Y, van Meerwijk JPM. CD28- and CD28lowCD8+
Regulatory T Cells: Of Mice and Men. Front Immunol. (2017) 8:31.
doi: 10.3389/fimmu.2017.00031
38. Rauch J, Salem D, Subang R, Kuwana M, Levine JS. β2-Glycoprotein I-
reactive T cells in autoimmune disease. Front Immunol. (2018) 9:2836.
doi: 10.3389/fimmu.2018.02836
39. Visvanathan S, McNeil HP. Cellular immunity to beta 2-glycoprotein-
1 in patients with the antiphospholipid syndrome. J Immunol. (1999) 1
62:6919–25.
40. Hattori N, Kuwana M, Kaburaki J, Mimori T, Ikeda Y, Kawakami Y. T cells
that are autoreactive to beta2-glycoprotein I in patients with antiphospholipid
syndrome and healthy individuals. Arthritis Rheum. (2000) 43:65–75. doi: 10.
1002/1529-0131(200001)43:1<65::AID-ANR9>3.0.CO;2-I
Frontiers in Immunology | www.frontiersin.org 11 March 2019 | Volume 10 | Article 391
Álvarez-Rodríguez et al. Th Cells in pAPS/SLE
41. Conti F, Spinelli FR, Alessandri C, Pacelli M, Ceccarelli F, Marocchi
E, et al. Subclinical atherosclerosis in systemic lupus erythematosus and
antiphospholipid syndrome: focus on β2GPI-specific T cell response.
Arterioscler Thromb Vasc Biol. (2014) 34:661–8. doi: 10.1161/ATVBAHA.
113.302680
42. Benagiano M, Gerosa M, Romagnoli J, Mahler M, Borghi MO, Grassi A, et
al. β2 Glycoprotein I recognition drives Th1 inflammation in atherosclerotic
plaques of patients with primary antiphospholipid syndrome. J Immunol.
(2017) 198:2640–8. doi: 10.4049/jimmunol.1600305
43. Vinuesa CG, Linterman MA, Yu D, MacLennan ICM. Follicular helper
T cells. Annu Rev Immunol. (2016) 34:335–68. doi: 10.1146/annurev-
immunol-041015-055605
44. Xie H, Sheng L, Zhou H, Yan J. The role of TLR4 in pathophysiology of
antiphospholipid syndrome-associated thrombosis and pregnancy morbidity.
Br J Haematol. (2014) 164:165–76. doi: 10.1111/bjh.12587
45. Cugno M, Borghi MO, Lonati LM, Ghiadoni L, Gerosa M, Grossi
C, et al. Patients with antiphospholipid syndrome display endothelial
perturbation. J Autoimmun. (2010) 34:105–10. doi: 10.1016/j.jaut.2009.
07.004
46. Knight JS, Meng H, Coit P, Yalavarthi S, Sule G, Gandhi AA, et al. Activated
signature of antiphospholipid syndrome neutrophils reveals potential
therapeutic target. JCI Insight. (2017) 2:93897. doi: 10.1172/jci.insight.93897
47. Viall CA, Chamley LW. Histopathology in the placentae of women with
antiphospholipid antibodies: a systematic review of the literature.Autoimmun
Rev. (2015) 14:446–71. doi: 10.1016/j.autrev.2015.01.008
48. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M,
Lanzavecchia A, et al. Surface phenotype and antigenic specificity of human
interleukin 17-producing T helper memory cells.Nat Immunol. (2007) 8:639–
46. doi: 10.1038/ni1467
49. Johnston LR, La Flamme AC, Larsen PD, Harding SA. Prasugrel inhibits
platelet-enhanced pro-inflammatory CD4+ T cell responses in humans.
Atherosclerosis. (2015) 239:283–6. doi: 10.1016/j.atherosclerosis.2015.01.006
50. An N, Chen Y, Wang C, Yang C, Wu ZH, Xue J, et al. Chloroquine autophagic
inhibition rebalances Th17/Treg-mediated immunity and ameliorates
systemic lupus erythematosus. Cell Physiol Biochem. (2017) 44:412–22.
doi: 10.1159/000484955
51. Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and
th1 T-cell responses in giant cell arteritis. Circulation. (2010) 121:906–15.
doi: 10.1161/CIRCULATIONAHA.109.872903
52. Banuelos J, Lu NZ. A gradient of glucocorticoid sensitivity among
helper T cell cytokines. Cytokine Growth Factor Rev. (2016) 31:27–35.
doi: 10.1016/j.cytogfr.2016.05.002
Conflict of Interest Statement: The authors declare that this study received
funding from Roche Farma (Spain). The funder was not involved in the study
design or collection, analysis, or interpretation of the data.
Copyright © 2019 Álvarez-Rodríguez, Martínez-Taboada, Calvo-Alén, Beares, Villa
and López-Hoyos. This is an open-access article distributed under the terms of
the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 12 March 2019 | Volume 10 | Article 391
